MedTrace Logo

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-02-20

No results posted yet for this study

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

repaglinide

Dose individually adjusted and conducted according to labeling

DRUG

glyburide

Dose individually adjusted and conducted according to labeling

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-08
Primary Completion
2003-03-13
Completion
2003-03-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01605773 on ClinicalTrials.gov